Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
46-60 of 355
Novel Strategies for Managing EGFR-mutated mNSCLC: Expert Insights into the Latest Data and Recommendations
CME/CENovel Strategies for Managing EGFR-mutated mNSCLC: Expert Insights into the Latest Data and Recommendations
Alexandria May, PharmD, BCPS
Helena A. Yu, MD
Vicki Sherry, DNP, ANP-BC, AOCNP
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
MinuteCE®Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Javier Cortes, MD, PhD
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
MinuteCE®Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
Tiffany Traina, MD
Tiffany Traina, MD
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
MinuteCE®Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Tiffany Traina, MD
Javier Cortes, MD, PhD
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
CME/CEPrecision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Susana Campos, MD, MPH
Robert Coleman, MD, FACOG
Debra Richardson, MD
- advertisement
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
CME/CEThe Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Cracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
CME/CECracking the Code in Localized, nmCSPC: Risk, Treatment, and Timing
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
MinuteCE®Winning the Battle Against Side Effects: Adverse Event Management in HSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Case: Implementing ADT Intensification in mHSPC
MinuteCE®Case: Implementing ADT Intensification in mHSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
De Novo mHSPC: Recognizing the Patients Who Need More
MinuteCE®De Novo mHSPC: Recognizing the Patients Who Need More
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
- advertisement
ADT Intensification: The Evidence You Can’t Afford to Miss
MinuteCE®ADT Intensification: The Evidence You Can’t Afford to Miss
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Molecular Profiling in mHSPC: Informing Treatment Selection
MinuteCE®Molecular Profiling in mHSPC: Informing Treatment Selection
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
